SCHEMBL6803416

SCHEMBL6803416

Cn1c(=O)n(CCCS)c(=O)c2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.60
HDAC1 Q13547 2/20 0.53
ERCC1 P07992 1/20 0.53
FEN1 P39748 1/20 0.53
ERCC4 Q92889 1/20 0.53
PGR P06401 2/20 0.50
SLC9A1 P19634 1/20 0.49
RORA P35398 1/20 0.49
RORC P51449 1/20 0.49
RORB Q92753 1/20 0.49
NPEPPS P55786 1/20 0.48
TSHR P16473 2/20 0.47
ALDH1A1 P00352 2/20 0.47
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6293988 0.88 KDM4E (0.56) TNFERCC1FEN1ERCC4PGR
SCHEMBL14560541 0.86 PGR (0.67) TNFHDAC1ERCC1FEN1ERCC4
SCHEMBL5036947 0.83 TNF (0.62) TNFHDAC1ERCC1FEN1ERCC4
SCHEMBL2858305 0.83 TNF (0.59) TNFHDAC1ERCC1FEN1ERCC4
SCHEMBL5037066 0.83 TNF (0.59) TNFHDAC1ERCC1FEN1ERCC4
SCHEMBL5033626 0.83 TNF (0.59) TNFHDAC1ERCC1FEN1ERCC4
SCHEMBL25936308 0.83 TOP2A (0.58) TNFHDAC1ERCC1FEN1ERCC4
SCHEMBL6295236 0.82 MAPK8 (0.55) PGRRORARORCRORBALDH1A1
SCHEMBL14692425 0.81 ERCC1 (0.56) TNFHDAC1ERCC1FEN1ERCC4
SCHEMBL6510771 0.81 ERCC1 (0.60) TNFHDAC1ERCC1FEN1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259192-A1 Method for cleaving the human growth hormone gh IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) 2004-12-23 US claimed
WO-2002074945-A1 METHOD FOR CLEAVING HUMAN GROWTH HORMONE GH IBFB GMBH PRIVATES INSTITUT FÜR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) 2002-09-26 WO claimed
US-20040259192-A1 Method for cleaving the human growth hormone gh IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) 2004-12-23 US disclosed
WO-2002074945-A1 METHOD FOR CLEAVING HUMAN GROWTH HORMONE GH IBFB GMBH PRIVATES INSTITUT FÜR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259192-A1 Method for cleaving the human growth hormone gh MMP3, MMP25, MMP17 TNF 475/4885HDAC1 870/4885ERCC1 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.